Logo Medical Data Models (MDM) Portal Logo Westfälische Wilhelms-Universität (WWU)
Information:
Error:
en ▾
  • Deutsch
  • English
  • Español
  • Italiano
  • Français
  • Português
  • Svenska
  • Nederlands
  • Login
  • Register
  • Search
  • ODM-XML file upload
  • Create data model
  • ODM-Edit tool
  • Metadata Registry
  • Help
  • About the MDM portal
  • Imprint
  • Login
  • Register
Actions ▾
  • ODM-XML file upload
  • Create data model
  • ODM-Edit tool
  • Metadata Registry
  • About the MDM portal
en ▾
  • Deutsch
  • English
  • Español
  • Italiano
  • Français
  • Português
  • Svenska
  • Nederlands

Search through specific fields of a model

The name of the data model contains study:
name:"study"
The description contains two terms:
description:"double blind"
The copyrightholder contains the term UKM:
copyrightholder:"UKM"
The uploader of the model is Martin Dugas:
uploader:"Martin Dugas"
The keywords contain cancer:
keyword:"cancer"

Refine the search with search operators

Search for groups of words with quotes:
"leukemia myeloid"
Use a wildcard to search for prefixes:
NCT*
With AND/OR/NOT find study without eye nor ear:
study AND NOT (eye OR ear)
Cancer must (+) occur, study not (-):
+cancer -study
You may connect the different search techniques:
name:"form*" AND routine
  • Filter search results
Keywords
Eligibility Determination ×
Leukemia ×
  • Clinical Trial  (114)
  • Hematology  (60)
  • AML  (17)
  • ALL  (6)
  • Neoplasms  (4)
  • Leukemia, Lymphoid  (3)
  • Leukemia, Lymphocytic, Chronic, B-Cell  (2)
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive  (2)
  • Hematopoietic Stem Cell Transplantation  (2)
  • Myelodysplastic Syndromes  (2)
  • Vaccination  (1)
  • Leukemia, Myeloid, Chronic-Phase  (1)
  • Lymphoma, T-Cell  (1)
  • Central Nervous System Neoplasms  (1)
  • Brain Neoplasms  (1)
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma  (1)
  • Doxorubicin  (1)
  • Lymphoma  (1)
  • Wilms Tumor  (1)
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
  • Select data models
Selected data models

You must log in to select data models for download or further analysis.

122 Search results.

Sort (Relevance) ▾
  • Relevance
  • Rating
  • New first
  • Old first

Eligibility Leukemia NCT02188706

- 6/25/20 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Leukemia SPORE Phase II Clinical Trial Comparing Decitabine Versus Decitabine/Carboplatin and Decitabine/Arsenic for the Treatment of Relapsed, Refractory, and Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS); ODM derived from: https://clinicaltrials.gov/show/NCT02188706
  • Leukemia
  • Clinical Trial
  • Eligibility Determination
  • Hematology

Eligibility Leukemia NCT02126553

- 6/25/20 - 1 form, 2 itemgroups, 19 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Lenalidomide Maintenance With High Risk (HR) Acute Myeloid Leukemia (AML) in Remission; ODM derived from: https://clinicaltrials.gov/show/NCT02126553
  • Hematology
  • Leukemia
  • Eligibility Determination
  • Clinical Trial

Eligibility Leukemia NCT02193100

- 6/25/20 - 1 form, 2 itemgroups, 15 items, 1 language
Itemgroups: Criteria, Exclusion Criteria
Pre and Post Treatment Metabolomic Analysis of Leukemia: A Translational Clinical Trial of the Brown Cancer Center; ODM derived from: https://clinicaltrials.gov/show/NCT02193100
  • Clinical Trial
  • Eligibility Determination
  • Leukemia
  • Hematology

Eligibility Leukemia NCT02272777

- 6/25/20 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase; ODM derived from: https://clinicaltrials.gov/show/NCT02272777
  • Hematology
  • Leukemia
  • Clinical Trial
  • Eligibility Determination

Eligibility Leukemia NCT01893320

- 6/24/20 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome; ODM derived from: https://clinicaltrials.gov/show/NCT01893320
  • Hematology
  • Leukemia
  • Eligibility Determination
  • Clinical Trial

Eligibility Leukemia NCT02096055

- 6/24/20 - 1 form, 2 itemgroups, 15 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
4-Arm Phase II Study of SGI-110 in Elderly Acute Myeloid Leukemia (AML); ODM derived from: https://clinicaltrials.gov/show/NCT02096055
  • Hematology
  • Eligibility Determination
  • Leukemia
  • Clinical Trial

Eligibility Leukemia NCT02096042

- 6/24/20 - 1 form, 2 itemgroups, 24 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML); ODM derived from: https://clinicaltrials.gov/show/NCT02096042
  • Eligibility Determination
  • Hematology
  • Leukemia
  • Clinical Trial

Eligibility Leukemia NCT02028039

- 6/24/20 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL); ODM derived from: https://clinicaltrials.gov/show/NCT02028039
  • Eligibility Determination
  • Hematology
  • Clinical Trial
  • Leukemia

Eligibility Leukemia NCT01692197

- 6/23/20 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes; ODM derived from: https://clinicaltrials.gov/show/NCT01692197
  • Leukemia
  • Eligibility Determination
  • Clinical Trial
  • Hematology

Eligibility Leukemia NCT01786343

- 6/23/20 - 1 form, 2 itemgroups, 8 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML); ODM derived from: https://clinicaltrials.gov/show/NCT01786343
  • Leukemia
  • Clinical Trial
  • Eligibility Determination
  • Hematology

Eligibility Leukemia NCT01664897

- 6/23/20 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Pilot Phase II - Erlotinib for Acute Myeloid Leukemia (AML); ODM derived from: https://clinicaltrials.gov/show/NCT01664897
  • Hematology
  • Eligibility Determination
  • Clinical Trial
  • Leukemia

Eligibility Leukemia NCT01891981

- 6/23/20 - 1 form, 2 itemgroups, 23 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Phase I/II Study of Moxetumomab; ODM derived from: https://clinicaltrials.gov/show/NCT01891981
  • Eligibility Determination
  • Clinical Trial
  • Leukemia
  • Hematology
  • 1
  • 2 (current)
  • 3
  • 4
  • 5
  • …
  • 11
  • >

Contact

Institute of Medical Informatics
Director: Prof. Dr. Martin Dugas
Albert-Schweitzer-Campus 1, A11
48149 Münster, Germany
Email : imi@uni-muenster.de

In collaboration with

Logo DFG Logo ERCIS Logo IMI Logo CatRIS Logo ULB Logo IH-D Logo Toolpool Logo EFMI
  • Imprint
  • Disclaimer
  • Data Privacy
© 2021  University of Münster
  • Contact
  • Help
  • Cite

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Login

Forgot password?


Register